MarketVIEW: Enterovirus-71 vaccines

Contents – Executive presentation (MS PowerPoint based)
Author’s note
Executive summary
Commercial model – key outputs
EV-71 vaccine(s): scenario definitions
Total available global market to 2030: EV-71 vaccine(s)
EV-71 vaccine: available market (0-5 yrs) to 2030
EV-71 vaccine: total predicted volume (0-5 yrs) to 2030
EV-71 vaccine: available market (<1 yrs) to 2030
EV-71 vaccine: available market (1-5 yrs) to 2030
EV-71 vaccine: China market to 2030 (0-5 yrs) to 2030
Total available global market to 2030: EV-71 vaccine(s) (public/private)
SE Asia: cumulative first 5 year spend (public)
Revenues per competitor to 2030: EV-71 vaccine(s) 0-5 yrs (CHINA)
EV-71: epidemiology overview
EV-71: the pathogen
Comparing endemic diseases
EV-71: timeline
Epidemiology: latest outbreaks in Asia
Epidemiology: incidence rates by country
Epidemiology: China
HFMD incidence rate, by province, January-May 2011, China
HFMD incidence rate, by province, January-May 9, 2008, China
Distribution of HFMD cases by province, January-May 2011, China
Distribution of severe HFMD cases (A) and deaths (B) by province, January-May 2011, China
Epidemiology: Taiwan
Epidemiology: Thailand
Epidemiology: Vietnam
Epidemiology: Malaysia
Epidemiology: South Korea
Epidemiology: Japan
HFMD annual and weekly cases, sentinel-reports, Japan
Percentage of HFMD cases by age group, sentinel-reports, 2000-2011
Virus isolation/detection from aseptic meningitis cases, 2008-2012, Japan
Epidemiology: Singapore
Epidemiology: US
Epidemiology: Europe
Epidemiology: Other
EV-71: mortality
EV-71: morbidity
EV-71 vaccine: modeling commercial potential
EV-71 vaccine opportunity: ideal target product profile
Modeling strategy: country/region inclusion
EV-71 vaccine commercial model: countries included/scenarios
Modeling strategy: target populations (endemic)
EV-71 vaccine: estimated order of vaccine use in target age groups
Modeling strategy: launch sequence/roll-out (endemic)
SE Asian countries: estimated launch dates per segment
Other countries: estimated launch dates per segment
EV-71: vaccine stockpile in Western countries?
EV-71: vaccine: cost effectiveness analysis
EV-71: prices used in model
EV-71: vaccinology, summary of competitor programs
EV-71: vaccine: immunological aspects
EV-71: summary of vaccine approaches to date
EV-71: vaccine: need for cross protection
Evidence for the possibility of single genotype vaccine for EV-71
Evidence against the possibility of single genotype vaccine for EV-71
EV-71 vaccine: cross protection – other points to note
Other Coxsackieviruses and HFMD
Vaccine pipeline
Estimating market share (CHINA)
Opportunity for new treatments
Bibliography
Disclaimer
About VacZine Analytics
PAGES: ~90 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model(s) (MS Excel-based)
Note: two models are included with differing vaccine price scenarios
Title sheet
Notes
CHARTS – VALUE
CHARTS VAL VOL
CHART – COMP
Competitors (0-5 yrs)
Value summary (0-5 yrs)
Volume summary (0-5 yrs)
Global price summary
LO SCENARIO
Public + private
Country 1 – <1 yrs + 1-5 yrs
Country 2 – <1 yrs + 1-5 yrs
Country 3 – <1 yrs + 1-5 yrs
etc
BASE SCENARIO
Public + private
Country 4 – <1 yrs + 1-5 yrs
Country 5 – <1 yrs + 1-5 yrs
HI SCENARIO
Public + private
Country 4 – <1 yrs + 1-5 yrs
Country 5 – <1 yrs + 1-5 yrs
Populations =>>
Birth cohorts
Epidemiology =>>
% pub/priv
% Urban population
Total populations
Back page
Worksheets = 35 per model

Vaccine in China

Drug and Medication in China